The non-age-restricted pill is expected to roll out early in 2024, and will ‘low...
The company aims to start two trials in H1 2024 based on its current timeline, d...
NVIDIA signed an investment and collaboration agreement with Recursion to create...
US FDA granted the IgG1 monoclonal antibody the first qualified infectious disea...
Health equity experts say public and financial accountability, solutions-based r...
A Boston Children’s Hospital team has developed a second personalized medicine, ...
Supplies are running out for dimercaprol, a key antidote for life-threatening le...
The European Union on Wednesday issued an antitrust fine of $475 million to the ...
From routing issues to unpredictable call volumes, staff say they’re proud of ho...
One way to blunt future drug shortages, the economists suggest, is to rework how...
A week after the FDA granted full, traditional approval to a new Alzheimer’s tre...
Hawken Miller joined the "First Opinion Podcast" this week to discuss how Sarept...
Pharmaceutical companies, governments, and the global health care community must...
At a Senate subcommittee hearing Tuesday, members discussed reforms that might a...
Takeda announced that it has voluntarily withdrawn its application to the FDA fo...
A new report resurfaces a thorny challenge in researchers’ quest to turn DNA int...